Table 2. Summary of pathological complete response rates in different subsets.
Site | All (n = 40) | HER2+ (n = 15) | TNBC (n = 15) | HR+ HER2- RS ≥ 25* (n = 10) |
---|---|---|---|---|
Breast only | 55(22) | 80 (12) | 46 (7) | 30(3) |
Breast and LN | 45(18) | 80 (12) | 40 (5) | 10(1) |
*HR+ HER2- RS ≥ 25: HR-positive, HER2-non-amplified with recurrence score ≥ 25 HER2+: human epidermal growth factor receptor type 2 amplified; TNBC: triple-negative breast cancer; HR: hormone receptor